Insider · CIK 0001722281
Cormac J Twomey
officer
Files at CNXC (Concentrix Corp). First filing Oct 29, 2024, latest Sep 2, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 11
$0 bought, $279k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CNXC: Concentrix Corp
CNXCOct 9, 2026 · close 25.95
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Concentrix Corp | $25k 500 shares | -1% | +44% from low-21% from high | |
| 0Weak | Concentrix Corp | $29k 500 shares | -1% | +51% from low-17% from high | |
| 0Weak | Concentrix Corp | $26k 500 shares | -1% | +44% from low-21% from high | |
| 0Weak | Concentrix Corp | $29k 500 shares | -1% | +52% from low-17% from high | |
| 0Weak | Concentrix Corp | $25k 500 shares | -1% | +39% from low-24% from high | |
| 0Weak | Concentrix Corp | $28k 500 shares | -1% | +50% from low-18% from high | |
| 0Weak | Concentrix Corp | $23k 500 shares | -1% | - | |
| 0Weak | Concentrix Corp | $28k 500 shares | -1% | - | |
| 0Weak | Concentrix Corp | $22k 500 shares | -2% | - | |
| 0Weak | Concentrix Corp | $23k 500 shares | -2% | - | |
| 0Weak | Concentrix Corp | $22k 500 shares | -2% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 29, 2025 | CNXC Concentrix Corp | SOpen-market sale Common Stock10b5-1 | -500 | $50.25 | $25k | 36,630 | Sep 2, 2025 |
| Jul 30, 2025 | CNXC Concentrix Corp | SOpen-market sale Common Stock10b5-1 | -500 | $57.91 | $29k | 37,130 | Jul 31, 2025 |
| Jun 30, 2025 | CNXC Concentrix Corp | SOpen-market sale Common Stock10b5-1 | -500 | $52.56 | $26k | 37,630 | Jul 2, 2025 |
| May 30, 2025 | CNXC Concentrix Corp | SOpen-market sale Common Stock10b5-1 | -500 | $57.06 | $29k | 38,130 | Jun 2, 2025 |
| Apr 30, 2025 | CNXC Concentrix Corp | SOpen-market sale Common Stock10b5-1 | -500 | $50.70 | $25k | 38,630 | May 1, 2025 |
| Mar 31, 2025 | CNXC Concentrix Corp | SOpen-market sale Common Stock10b5-1 | -500 | $55.31 | $28k | 39,130 | Apr 2, 2025 |
| Feb 28, 2025 | CNXC Concentrix Corp | SOpen-market sale Common Stock10b5-1 | -500 | $45.14 | $23k | 39,630 | Mar 4, 2025 |
| Feb 1, 2025 | CNXC Concentrix Corp | FTax withholding Common Stock | -1,439 | $52.28 | $75k | 40,130 | Feb 3, 2025 |
| Jan 29, 2025 | CNXC Concentrix Corp | SOpen-market sale Common Stock10b5-1 | -500 | $55.60 | $28k | 41,111 | Jan 31, 2025 |
| Jan 29, 2025 | CNXC Concentrix Corp | AGrant or award Common Stock10b5-1 | +866 | $0.00 | $0 | 41,977 | Jan 31, 2025 |
| Jan 29, 2025 | CNXC Concentrix Corp | FTax withholding Common Stock10b5-1 | -408 | $53.96 | $22k | 41,569 | Jan 31, 2025 |
| Jan 24, 2025 | CNXC Concentrix Corp | AGrant or award Common Stock | +18,462 | $0.00 | $0 | 42,398 | Jan 28, 2025 |
| Jan 26, 2025 | CNXC Concentrix Corp | FTax withholding Common Stock | -292 | $52.54 | $15k | 42,106 | Jan 28, 2025 |
| Jan 27, 2025 | CNXC Concentrix Corp | FTax withholding Common Stock | -495 | $53.51 | $26k | 41,611 | Jan 28, 2025 |
| Dec 30, 2024 | CNXC Concentrix Corp | SOpen-market sale Common Stock10b5-1 | -500 | $44.05 | $22k | 23,936 | Dec 31, 2024 |
| Nov 29, 2024 | CNXC Concentrix Corp | SOpen-market sale Common Stock10b5-1 | -500 | $45.15 | $23k | 24,436 | Dec 3, 2024 |
| Oct 29, 2024 | CNXC Concentrix Corp | SOpen-market sale Common Stock10b5-1 | -500 | $44.18 | $22k | 24,936 | Oct 29, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.